Results 161 to 170 of about 146,874 (392)
International Journal of Cancer, EarlyView.Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea +5 more
wiley +1 more source
iRADIOLOGY, EarlyView.The role of PET/CT in the management of ovarian cancer at each disease stage, including primary detection, staging, prognosis evaluation, treatment response assessment and recurrence surveillance, and its future potential in relation to novel non‐FDG radiotracers, PET/MRI, dynamic PET and AI‐based radiomics.
Caiyun Xu +4 more
wiley +1 more source
Macromolecular Bioscience, EarlyView.This study reports on the in vitro, ex vivo, and in vivo evaluation of HER2 targeted biodegradable micelle variants, conjugated with trastuzumab, with or without the drug doxorubicin or the dye rhodamine B. Findings indicate enhanced cellular association and efficacy of trastuzumab‐conjugated micelles in HER2 positive breast cancer models, showing ...
Remya Valsala Kumari +11 more
wiley +1 more source
Trastuzumab in the treatment of advanced breast cancer: Single-center experience [PDF]
, 2001 Mirando Mršić +8 more
openalex +1 more source
Macromolecular Bioscience, EarlyView.Vascularized tumor‐on‐a‐chip platforms replicate human tumor microenvironments by integrating perfusable vessels and stromal elements in microfluidic systems. These models enable dynamic assessment of drug delivery and therapeutic response under physiologically relevant flow, offering enhanced predictive value for cancer treatment.
Hyelim Kim +2 more
wiley +1 more source
مجله دانشگاه علوم پزشکی بیرجند, 2017 Background and Aim: Resistance to trastuzumab has been a critical barrier to targeted therapy of HER 2-positive (Human Epidermal Growth Factor Receptor 2) breast cancers.
Zohreh Rezaei +3 more
doaj
Medicinal Research Reviews, EarlyView.ABSTRACT Targeted radioligand therapy has emerged as a promising treatment option for eradicating advanced cancer forms. α‐Emitters are considered particularly promising as they can obliterate (micro)‐metastases. The α‐emitter astatine‐211 (211At) has experienced increased interest due to its favorable decay properties.
Marius Müller +5 more
wiley +1 more source
eLifeTrastuzumab resistance remains a challenge for HER2-positive breast cancer treatment. Targeting metabolic reprogramming would provide novel insights for therapeutic strategies.
Yijia Hua +13 more
doaj +1 more source